Lowering fibrinogen levels: Clinical update

Blood Coagulation and Fibrinolysis

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Behar, S ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002154331     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
2. Stone MC, Thorp J. Plasma fibrinogen: a major coronary risk factor. J R Col Gen Pract 1985; 35: 564-569.
3. Kannel WB, D'Agostino RB, Belanger AJ. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992; 2: 457-166.
4. Yarnell JWG, Baker IA, Sweetnam PM, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991; 83: 836-844.
5. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-59.
6. Meade TW, Mllows W, Brozovic M, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart study. Lancet 1986; ii: 533-537.
7. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta analysis and review of the literature. Ann Intern Med 1996; 118:956-963.
8. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U, for the Bezafibrate Infarction Prevention (BIP) Study Group. Fibrinogen is a predictor of mortality in coronary heart disease patients. Arterioscler Throm Vasc Biol 1996; 16: 351-356.
9. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H. Fibrinogen is a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J 1998; 19: 55-62.
10. Rosengren A, Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and non-smokers. The study of men born in 1933. J Intern Med 1996; 239: 499-507.
11. Kovacs IB, Ratnatunga CP, Ridler CD, Gorog P, Edmondson SJ, Rees GM. Significance of plasma fibrinogen in coronary arterial disease: marker or causative risk factor for arterial thrombosis? Int J Cardiol 1992; 35: 57-64.
12. Fowkes FG. Fibrinogen and cardiovascular disease in clinical practice. Eur Heart J 1995; Suppl A: 60-63.
13. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, et al. for the Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinical manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993; 71: 909-915.
14. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H, for the BIP Study Group. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) study. Eur Heart J 1998; 19 (Suppl H): H42-H47.
15. Hemker HC, Kop J, Willems GM. Kinetic aspects of the interaction of blood clotting enzymes. VII: the relation between clotting time and clotting velocity. Thromb Haemost 1979; 41: 309-313.